Thomas Fuchs

Thomas joined Mosaic as Chief Executive Officer in October 2025, bringing over 25 years' experience in leadership positions across early drug development, commercialisation and life cycle management in both oncology-focused biotech and big pharma.

He was most recently CEO at Cimeio Therapeutics, where he led the early company build backed by a $50M series A financing raise and secured a significant strategic collaboration agreement with Kyowa Kirin. Previously, Thomas spent 15 years at Roche-Genentech, serving in senior leadership roles across the Global Haematology franchise. As Global Franchise Head, he oversaw development strategy, life cycle management and commercialisation of Roche-Genentech's haematology portfolio, covering five marketed products with over $8Bn sales.

Thomas holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science in Business Administration from the University of Wisconsin-Stout.